Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Priya Life Science Sponsor trial record
Sponsor · clinical trials

City of Hope Medical Center clinical trials

Source: ClinicalTrials.gov, U.S. National Library of Medicine — current trials in our Japan, Egypt, Spain, China, Italy, Canada, Mexico, South Korea and Israel registers with City of Hope Medical Center as lead sponsor. Synced 17 Nov 2026
17Current trials
14Recruiting now
39Drugs in these trials
9Trial registers
At a glance

City of Hope Medical Center is the lead sponsor of 17 current clinical trials in our Japan, Egypt, Spain, China, Italy, Canada, Mexico, South Korea and Israel registers. 14 are recruiting patients now. The most common phase is Observational. The drugs named most often in its trials are Avastin, BP102 and Bevacizumab. The most-studied condition is Colorectal Cancer.

ClinicalTrials.gov trials by status

  • Recruiting1482%
  • Not yet open16%
  • Active, closed212%

Trials by phase

  • Observational1059%
  • Phase 2424%
  • Phase 116%
  • Phase 316%
  • Not applicable16%
01

Clinical trials sponsored by City of Hope Medical Center

17 on ClinicalTrials.gov
StudyPhaseStatusStartRegisters
An Exosome-Based Liquid Biopsy for the Differential Diagnosis of Primary Liver Cancer
NCT06342414 · ClinicalTrials.gov ↗ · Hepatocellular Carcinoma, Intrahepatic Cholangiocarcinoma, Cholangiocarcinoma
Observational Recruiting 2024-03 Japan
Predicting Postoperative Chemotherapy Efficacy in Patients With Esophageal Squamous Cell Carcinoma
NCT06490003 · ClinicalTrials.gov ↗ · Esophageal Squamous Cell Carcinoma, Chemotherapy Effect, DNA Methylation
Drug: Cisplatin
Observational Recruiting 2004-06 Japan
Predicting Early Tumor Recurrence in Patients With Esophageal Squamous Cell Carcinoma
NCT06476067 · ClinicalTrials.gov ↗ · Esophageal Cancer, Recurrence, DNA Methylation
Observational Recruiting 2006-01 Japan
Molecular Genetics Studies of Cancer Patients and Their Relatives
NCT04185935 · ClinicalTrials.gov ↗ · Malignant Neoplasm
Observational Recruiting 1997-04 Mexico
Pancreatic Cancer Detection Consortium
NCT06388967 · ClinicalTrials.gov ↗ · Pancreatic Cancer, Pancreatic Carcinoma, Pancreatic Adenocarcinoma
Observational Recruiting 2023-03 Japan, South Korea
Early Onset Colorectal Cancer Detection
NCT06342401 · ClinicalTrials.gov ↗ · Colorectal Cancer, Colorectal Neoplasms, Colorectal Adenocarcinoma
Observational Recruiting 2023-04 Spain, Italy, Japan
A Multicenter Prospective Observational Cohort Study Evaluating the Impact of Cancer-Directed Treatment and Medication Use, Including Cannabis Use, in Multiple Myeloma Patients
NCT07225738 · ClinicalTrials.gov ↗ · Multiple Myeloma
Observational Recruiting 2026-01 Egypt
Immunotherapy Biomarkers to Predict First-line PD(L)1-based Immunotherapy Response and Selection of Second-line Treatment in Stage IIIB-IV Non-small Cell Lung Cancer, IMMUNO-BIOMAP Trial
NCT07288034 · ClinicalTrials.gov ↗ · Lung Non-Small Cell Carcinoma, Stage IIIB Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8
Phase 2 Recruiting 2026-05 Egypt
Pressurized Intraperitoneal Aerosolized Chemotherapy With Mitomycin for the Treatment of Unresectable Appendix or Colorectal Cancer With Peritoneal Metastases, The IMPACT Trial
NCT07271355 · ClinicalTrials.gov ↗ · Metastatic Appendix Carcinoma, Metastatic Colorectal Carcinoma, Metastatic Malignant Neoplasm in the Peritoneum
Phase 3 Recruiting 2027-01 Egypt
Early Detection of Advanced Adenomas and Colorectal Cancer
NCT06342440 · ClinicalTrials.gov ↗ · Colorectal Cancer, Colorectal Neoplasms, Colorectal Polyp
Observational Recruiting 2020-03 China, Spain, Italy, Japan
Neoadjuvant Botensilimab and Balstilimab for the Treatment of Advanced Resectable Colorectal Cancer NEST3
NCT07595874 · ClinicalTrials.gov ↗ · Advanced Colon Adenocarcinoma, Advanced Colorectal Adenocarcinoma, Advanced Rectal Adenocarcinoma
Phase 2 Recruiting 2026-07 Egypt
Minimal Residual Disease Testing for the Early Detection of Cancer Recurrence in Resectable Stage II-IV Colorectal Cancer Patients
NCT07125729 · ClinicalTrials.gov ↗ · Resectable Colorectal Carcinoma, Stage II Colorectal Cancer AJCC v8, Stage III Colorectal Cancer AJCC v8
Not applicable Recruiting 2025-08 Egypt
Predicting Peripheral Neuropathy of Paclitaxel for Gastric Cancer
NCT06490159 · ClinicalTrials.gov ↗ · Gastric Cancer, Chemotherapy-induced Peripheral Neuropathy, Paclitaxel
Observational Recruiting 2018-10 Japan
Stage II/III Colorectal Cancer Recurrence
NCT06314958 · ClinicalTrials.gov ↗ · Colorectal Cancer, Colorectal Adenocarcinoma, Colorectal Cancer Stage II
Observational Recruiting 2023-03 China, Spain
CCR5 Targeting Leronlimab in Combination With Hepatic Arterial Infusion Floxuridine and Systemic Therapy for the Treatment of Colorectal Cancer Liver Metastases, CHAMP Trial
NCT07842965 · ClinicalTrials.gov ↗ · Metastatic Colorectal Carcinoma, Metastatic Malignant Neoplasm in the Liver, Stage IV Colorectal Cancer AJCC v8
Phase 1 Not yet open 2027-05 Egypt
Brentuximab Vedotin and Nivolumab in Treating Patients With Early Stage Classic Hodgkin Lymphoma
NCT03712202 · ClinicalTrials.gov ↗ · Ann Arbor Stage I Hodgkin Lymphoma, Ann Arbor Stage I Mixed Cellularity Classic Hodgkin Lymphoma, Ann Arbor Stage I Nodular Sclerosis Classic Hodgkin Lymphoma
Phase 2 Active, closed 2018-11 Israel
Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With CD30-Positive Peripheral T-cell Lymphoma
NCT03113500 · ClinicalTrials.gov ↗ · Adult T-Cell Leukemia/Lymphoma, Anaplastic Large Cell Lymphoma, ALK-Negative, Anaplastic Large Cell Lymphoma, ALK-Positive
Phase 2 Active, closed 2017-12 Canada

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.

02

Drugs in City of Hope Medical Center trials

39 compounds

Drugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.

03

Conditions in City of Hope Medical Center trials

50 conditions
Colorectal Cancer3Colorectal Adenocarcinoma3Colorectal Neoplasms2DNA Methylation2Metastatic Colorectal Carcinoma2Stage IV Colorectal Cancer AJCC v82Colorectal Cancer Stage II1Colorectal Cancer Stage III1Colorectal Polyp1Colorectal Cancer Stage I1Adult T-Cell Leukemia/Lymphoma1Anaplastic Large Cell Lymphoma, ALK-Negative1Anaplastic Large Cell Lymphoma, ALK-Positive1Angioimmunoblastic T-Cell Lymphoma1Malignant Neoplasm1Hepatocellular Carcinoma1Intrahepatic Cholangiocarcinoma1Cholangiocarcinoma1Primary Liver Cancer1Esophageal Squamous Cell Carcinoma1Chemotherapy Effect1Esophageal Cancer1Recurrence1Pancreatic Cancer1
06

Questions about City of Hope Medical Center trials

How many clinical trials does City of Hope Medical Center sponsor?

City of Hope Medical Center is the lead sponsor of 17 current trials on ClinicalTrials.gov in our Japan, Egypt, Spain, China, Italy, Canada, Mexico, South Korea and Israel registers, as of the registry sync on 17 November 2026. Completed and withdrawn studies are not counted.

Are City of Hope Medical Center trials recruiting?

Yes. 14 of its 17 ClinicalTrials.gov trials are recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Which drugs is City of Hope Medical Center testing?

Its current trials name 39 drugs and biologicals as interventions. The most frequent are Avastin (2), BP102 (2), Bevacizumab (2), Bevacizumab-awwb (2) and Brentuximab Vedotin (2). The number in brackets is how many of its trials name each drug.

Where does this information come from?

Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.

Approvals, shortages and trials, every Friday

One email a week with new EMA and FDA approvals, EU and US medicine shortages, how many trials are recruiting in Ireland, and the week's Irish pharma news.

Free. Unsubscribe from any email with one click. See our privacy policy.

How this page is built

Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.

This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 17 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.